In February JSC Grindeks has been admitted to Latvia Biotechnology Association (LBA). Membership at the Association gives opportunity to the company to follow all the current events of the field, to take part in promotion and development of the industry as well as find ideas for perspective projects in biotechnologies. As stressed out by Vitālijs Skrīvelis, Member of the board of JSC Grindeks and the new authorized representative at the Association: “The chemically synthesized medicals in new medical products creative process have to some extent emptied themselves and the science is continuing to develop rapidly, seeking for new humans curing methods. The employment of Biotechnologies in medical field opens opportunities for creation of new and effective medicines, giving the possibility to cure such hard diseases as cancer, HIV etc.” By focusing to biotechnology, Grindeks testifies its readiness to provide a sustainable development of science, research and technologies. Company can boast of strong scientific potential - high rang professionals, who are working with synthetic medicines, and by acquiring new knowledge and methods, could successfully form industrial technologies in the field of biotechnologies in future, pointed out V.Skrīvelis. The determination to turn to the perspective field of biotechnologies, Grindeks acknowledged already in 2006, by concluding an agreement with Biomedical Research and Study Centre of Latvia about mutual cooperation in carrying out research and innovation activities. Grindeks is the leading pharmaceutical company in the Baltic States specializing in the manufacturing and sales of heart and cardiovascular, central nervous system and anti-cancer medications. Its concern consists of four subsidiary companies in Latvia, Estonia and Russia as well as seven representative offices. Products of the company are exported to more than 40 countries. Main markets - Baltic States, Russia and other CIS countries, Japan, USA. Grindeks shares are listed in the Official list of Riga Stock Exchange. Information was prepared by: Ilze Kreicmane JSC Grindeks Acting Head of Communications Department Office : 7083336 GSM : 26466681 e-mail : ilze_kreicmane@grindeks.lv www.grindeks.lv